Skip to main content

Table 1 Baseline clinical and treatment characteristics of the primary cohort and validation cohort

From: Development and external validation of a nomogram to predict overall survival following stereotactic body radiotherapy for early-stage lung cancer

Variable

Primary cohort

Validation cohort

Total N

N or Median (% or range)

Total N

N or Median (% or range)

Age

587

75 (44–91)

124

77 (48–90)

Sex

587

 

124

 

 Female

 

224 (38%)

 

46 (37.1%)

 Male

 

363 (62%)

 

78 (62.9%)

KPS

581

 

124

 

  ≥ 90

 

117 (20%)

 

54 (43.5%)

 70–80

 

395 (68%)

 

62 (50.0%)

  ≤ 60

 

69 (12%)

 

8 (6.5%)

Operable

581

40 (7%)

124

10 (8.1%)

CCI

587

3 (0–10)

124

2 (0–9)

CIRS

587

5 (0–15)

124

5 (0–16)

Current/former smoker

521

481 (92%)

  

GOLD score

580

   

 1

 

97 (17%)

  

 2

 

240 (41%)

  

 3

 

144 (25%)

  

 4

 

37 (6%)

  

Previous malignancy

587

237 (40%)

  

Previous lung cancer

587

120 (20.4%)

  

T stage

587

 

124

 

 T1

 

412 (70%)

 

13 (10.5%)

 T2

 

147 (25%)

 

55 (44.4%)

 T3

 

28 (5%)

 

42 (33.9%)

 T4

 

0 (0%)

 

14 (11.3%)

Tumor diameter

587

2.3 cm (0.7–7.7)

124

4.6 cm (1.4–10.5)

Pathology

587

 

124

 

 Unknown

 

329 (56%)

  

 Squamous cell carcinoma

 

94 (16%)

  

 Adenocarcinoma

 

103 (18%)

  

 Large cell carcinoma

 

51 (9%)

  

 Other

 

10 (2%)

  

Dose fractionation

587

 

124

 

 60 Gy/3

 

209 (36%)

  

 54 Gy/3

 

15 (3%)

  

 51 Gy/3

 

354 (60%)

  

 40 Gy/2

 

1 (0.2%)

  

 60 Gy/5

 

8 (1%)

  

 55 Gy/5

   

48 (38.4%)

 48 Gy/6

   

19 (15.2%)

 49 Gy/7

   

17 (13.7%)

 60 Gy/5

   

18 (14.4%)

 Other

   

22 (17.6%)

  1. Abbreviations: CCI Charlson Comorbidity Index score, CIRS Cumulative Illness Rating Score, GOLD Global Initiative for Chronic Obstructive Lung Disease, KPS Karnofsky Performance Status